Beyond TROP2 NMR: AI & Computational Pathology for IHC-Based Diagnostics

• Describing how QCS delivers human interpretable features beyond Normalized Membrane Ratio (NMR) for biomarker Dx development
• Discussing the future of computational pathology-based IHC diagnostics including the use of controls
• Examining the future of AI in the development of multimodal-based diagnostics

Speakers:

Mark Gustavson

Senior Director, Computational Pathology

AstraZeneca